Research programme: immunotherapy and gene inhibition - Juvaris/SomaGenics
Alternative Names: Immunotherapy and gene inhibition research programme - Juvaris/SomaGenicsLatest Information Update: 26 Dec 2014
At a glance
- Originator Juvaris BioTherapeutics; SomaGenics
- Class DNA; Lipids; RNA
- Mechanism of Action Genetic transcription inhibitors; Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Anthrax
Most Recent Events
- 02 Jun 2004 Preclinical trials in Anthrax in USA (unspecified route)